Тип публикации: статья из журнала

Год издания: 2017

Идентификатор DOI: 10.1134/S0026893317040148

Ключевые слова: aberrant methylation, antitumor therapy, circulating DNA, LINE-1 retrotransposons, lung cancer, prognosis

Аннотация: Malignant cell transformation is accompanied with abnormal DNA methylation, such as the hypermethylation of certain gene promoters and hypomethylation of retrotransposons. In particular, the hypomethylation of the human-specific family of LINE-1 retrotransposons was observed in lung cancer tissues. It is also known that the circulaПоказать полностьюting DNA (cirDNA) of blood plasma and cell-surface-bound circulating DNA (csb-cirDNA) of cancer patients accumulate tumor-specific aberrantly methylated DNA fragments, which are currently considered to be valuable cancer markers. This work compares LINE-1 retrotransposon methylation patterns in cirDNA of 16 lung cancer patients before and after treatment. CirDNA was isolated from blood plasma, and csb-cirDNA fractions were obtained by successive elution with EDTA-containing phosphate buffered saline and trypsin. Concentrations of methylated LINE-1 region 1 copies (LINE-1-met) were assayed by real-time methylation-specific PCR. LINE-1 methylation levels were normalized to the concentration of LINE-1 region 2, which was independent of the methylation status (LINE-1-Ind). The concentrations of LINE-1-met and LINE-1-Ind in csb-cirDNA of lung cancer patients exhibited correlations before treatment (r = 0.54), after chemotherapy (r = 0.72), and after surgery (r = 0.83) (P 0.05, respectively). These results suggest a need for the further investigation of dynamic changes in levels of LINE-1 methylation depending on the antitumor therapy. © 2017, Pleiades Publishing, Inc.

Журнал: Molecular Biology

Выпуск журнала: Vol. 51, Is. 4

Номера страниц: 549-554

ISSN журнала: 00268933

Издатель: Maik Nauka Publishing / Springer SBM

• Ponomaryova A.A. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation, Tomsk Polytechnical University, Tomsk, Russian Federation)
• Cherdyntseva N.V. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation, Тomsk State University, Tomsk, Russian Federation)
• Bondar A.A. (Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation)
• Dobrodeev A.Y. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation)
• Zavyalov A.A. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation)
• Tuzikov S.A. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation)
• Vlassov V.V. (Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation)
• Choinzonov E.L. (Tomsk National Center for Medical Research, Russian Academy of Sciences, Tomsk, Russian Federation)
• Laktionov P.P. (Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation, Meshalkin Siberian Federal Biomedical Research Center, Novosibirsk, Russian Federation)
• Rykova E.Y. (Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation, Novosibirsk State Technical University, Novosibirsk, Russian Federation)

• Scopus